Compare FNWD & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | KLRS |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 144.9M |
| IPO Year | 1996 | N/A |
| Metric | FNWD | KLRS |
|---|---|---|
| Price | $33.39 | $6.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $37.50 | $19.00 |
| AVG Volume (30 Days) | 2.8K | ★ 80.5K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $17.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.46 | $2.14 |
| 52 Week High | $39.99 | $11.88 |
| Indicator | FNWD | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 43.62 |
| Support Level | $31.52 | $5.26 |
| Resistance Level | $38.79 | $7.18 |
| Average True Range (ATR) | 0.75 | 0.59 |
| MACD | -0.17 | 0.15 |
| Stochastic Oscillator | 52.17 | 47.09 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.